Class information for:
Level 1: ANILINOQUINAZOLINE//COMBI MOLECULE//CANC DRUG

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
11029 948 36.7 81%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
451 15419 HER 2//TRASTUZUMAB//LAPATINIB

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ANILINOQUINAZOLINE Author keyword 53 95% 2% 18
2 COMBI MOLECULE Author keyword 18 89% 1% 8
3 CANC DRUG Address 15 73% 1% 11
4 MED ONCOL MEDCANC DRUG Address 14 100% 1% 7
5 4 ANILINOQUINAZOLINE Author keyword 11 69% 1% 9
6 QUINAZOLINE Author keyword 10 16% 6% 57
7 EGFR TK INHIBITORS Author keyword 9 83% 1% 5
8 EGFR TK Author keyword 8 70% 1% 7
9 4 AMINOQUINAZOLINE Author keyword 8 75% 1% 6
10 CANC DRUG MED MED ONCOL Address 8 100% 1% 5

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 ANILINOQUINAZOLINE 53 95% 2% 18 Search ANILINOQUINAZOLINE Search ANILINOQUINAZOLINE
2 COMBI MOLECULE 18 89% 1% 8 Search COMBI+MOLECULE Search COMBI+MOLECULE
3 4 ANILINOQUINAZOLINE 11 69% 1% 9 Search 4+ANILINOQUINAZOLINE Search 4+ANILINOQUINAZOLINE
4 QUINAZOLINE 10 16% 6% 57 Search QUINAZOLINE Search QUINAZOLINE
5 EGFR TK INHIBITORS 9 83% 1% 5 Search EGFR+TK+INHIBITORS Search EGFR+TK+INHIBITORS
6 EGFR TK 8 70% 1% 7 Search EGFR+TK Search EGFR+TK
7 4 AMINOQUINAZOLINE 8 75% 1% 6 Search 4+AMINOQUINAZOLINE Search 4+AMINOQUINAZOLINE
8 4 ANILINOQUINAZOLINES 7 67% 1% 6 Search 4+ANILINOQUINAZOLINES Search 4+ANILINOQUINAZOLINES
9 TYRPHOSTINS 6 29% 2% 18 Search TYRPHOSTINS Search TYRPHOSTINS
10 AG957 4 75% 0% 3 Search AG957 Search AG957

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 BINDING SITE INHIBITORS 33 74% 3% 25
2 4 PHENYLAMINOQUINAZOLINE 32 85% 2% 17
3 OVEREXPRESSING TUMORS 26 100% 1% 11
4 IRREVERSIBLE INHIBITORS 26 27% 9% 85
5 PUTATIVE IRREVERSIBLE INHIBITOR 23 86% 1% 12
6 4 ANILINOQUINAZOLINES 22 66% 2% 21
7 4 ANILINOQUINAZOLINE 21 90% 1% 9
8 TRIAZENE SMA41 18 89% 1% 8
9 ERBSTATIN 17 49% 3% 25
10 TARGETING CONCEPT 17 100% 1% 8

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
The resurgence of covalent drugs 2011 251 58 16%
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome 2013 58 72 22%
TYROSINE KINASE INHIBITION - AN APPROACH TO DRUG DEVELOPMENT 1995 1368 88 34%
The development of HKI-272 and related compounds for the treatment of cancer 2008 61 47 40%
Targeted covalent drugs of the kinase family 2010 54 30 30%
Irreversible Protein Kinase Inhibitors 2011 24 48 52%
Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance 2013 36 96 17%
Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography 2008 27 24 50%
Radiolabeled Small Molecule Protein Kinase Inhibitors for Imaging with PET or SPECT 2010 22 77 45%
Tyrphostins and other tyrosine kinase inhibitors 2006 103 100 30%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CANC DRUG 15 73% 1.2% 11
2 MED ONCOL MEDCANC DRUG 14 100% 0.7% 7
3 CANC DRUG MED MED ONCOL 8 100% 0.5% 5
4 MED MED ONCOLCANC DRUG 8 100% 0.5% 5
5 MED ONCOLCANC DRUG 8 100% 0.5% 5
6 CONSUMER CLIN RADIAT PROTECT BUR 2 16% 1.4% 13
7 MEDCANC DRUG 2 67% 0.2% 2
8 SHIONOGI MED S 2 67% 0.2% 2
9 ZISE LA POMPELLE 2 67% 0.2% 2
10 ZI POMPELLE 2 24% 0.6% 6

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000213715 DIARYLAMIDE//VEGFR 2 INHIBITOR//KDR KINASE
2 0.0000130279 NIMOTUZUMAB//H R3//CETUXIMAB
3 0.0000120339 OSI 420//OSI 774//CAKI 1 RENAL CELL CARCINOMA
4 0.0000096266 LCK INHIBITOR//SRC INHIBITORS//SRC
5 0.0000094043 QUINAZOLINONE//43H QUINAZOLINONES//2 3 DIHYDROQUINAZOLIN 41H ONES
6 0.0000087310 GEFITINIB//ERLOTINIB//EGFR MUTATION
7 0.0000078300 IMMUNOGENE//MED MOLEC BIOL SHINJUKU KU//ERBB PROTEINS
8 0.0000064344 RATIOMETRIC FLUORESCENCE ANALYSIS//GENISTEIN INHIBITION//ISOBESTIC FLUORESCENCE ANALYSIS
9 0.0000061742 BREAST CARCINOMA CELL LINE//BIOTINYLATED EPIDERMAL GROWTH FACTOR//BREAST CANCER BIOPSIES
10 0.0000061701 DEHYDRON//KINASE TARGETING//ONCOKINOME